Personalized Models for Cancer Research

Status Recruiting

Clinical Trial Summary

The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate cancer research ranging from disease mechanisms to personalized medicine approaches that will help to realize the promise of precision medicine for oncology.

Clinical Trial Description

Researchers at the New York Stem Cell Foundation (NYSCF) Research Institute will establish a living biobank of tumor/organoids and stem cells representing individual patients diagnosed with cancer. Samples from healthy individuals (non-cancer diagnosis) or from non-disease tissue will also be collected to be used as controls in this study. Information and biospecimens may be transferred to NYSCF by external institution or NYSCF research personnel may prospectively enroll participants to have portions of samples or cells that were (or will be) collected for reasons other than this study transferred into the biobank. NYSCF's researchers hypothesize that the development of patient-specific models that can expand in vitro while capturing tumor complexity at the genotypic and phenotypic levels will enable accelerated discovery of more efficient treatments for patients and improve outcomes. This study is not a clinical trial. ;

Study Design

Related Conditions & MeSH terms

Solid Tumor, Adult

Clinical Trial Details

NCT number	NCT06350539
Study type	Observational
Source	New York Stem Cell Foundation Research Institute
Contact	Becca Wood
Phone	212-927-1801
Email	clinicalresearch@nyscf.org
Status	Recruiting
Phase
Start date	February 15, 2024
Completion date	February 15, 2034

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT04551885` - FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors	Phase 1
Active, not recruiting	`NCT05054348` - First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors	Phase 1
Active, not recruiting	`NCT04474470` - A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer	Phase 1/Phase 2
Recruiting	`NCT06088004` - Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 Monotherapy in Advanced Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT05055609` - Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors	Phase 1
Completed	`NCT04020185` - Safety and Efficacy Study of IMSA101 in Refractory Malignancies	Phase 1/Phase 2
Withdrawn	`NCT05071846` - MVX-ONCO-2 in Advanced Solid Tumors	Phase 1
Recruiting	`NCT05607199` - A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics	Phase 1
Active, not recruiting	`NCT04552288` - Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies	Phase 2
Active, not recruiting	`NCT06026254` - A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial	Phase 1
Recruiting	`NCT06032845` - Cryoablation Combined With Tislelizumab Plus Lenvatinib In Previously Treated Solid Tumors (CASTLE-11)	Phase 2
Recruiting	`NCT06144671` - GT201 Injection For The Treatment Of Advanced Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT05276284` - Thiopurine Enhanced Mutations for PD-1/Ligand-1 Efficacy	Phase 1/Phase 2
Recruiting	`NCT04121442` - Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors	Phase 1/Phase 2
Active, not recruiting	`NCT04221204` - A Monotherapy in Subjects With Advanced Solid Tumors	Phase 1
Terminated	`NCT03992326` - Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes in Solid Tumors	Phase 1
Active, not recruiting	`NCT05435339` - A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tumors as Monotherapy	Phase 1/Phase 2
Recruiting	`NCT04981119` - Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Recruiting	`NCT06075849` - Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent	Phase 1
Recruiting	`NCT04092673` - Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies	Phase 1/Phase 2